Navigation Links
Cellular Dynamics Announces Presentations at the Society of Toxicology's 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
Date:3/8/2013

; University of Glasgow and Clyde Biosciences) present data on the utility and suitability of a novel optical platform that when used in conjunction with iCell Cardiomyocytes can assess new chemical entity (NCE)-mediated proarrhythmia with an order of magnitude greater throughput than manual patch clamp methods without loss of sensitivity.

Sirenko, O et al. (Abstract 86, poster 120; Molecular Devices and University of North Carolina - Chapel Hill) describe methods for measuring the impact of drug compounds on iCell Cardiomyocytes' beat rate using fast kinetic fluorescence imaging, thus incorporating high throughput screening in proarrhythmia testing.

Qin, S et al. (Abstract 89, poster 123; Cyprotex and Axion Biosystems) demonstrate the use of multi-well multi-electrode arrays (MEAs) as an effective tool to screen for cardiotoxic liabilities in iCell Cardiomyocytes.

Yego, EK et al. (Abstract 363, poster 628; US Army Medical Research Institute of Chemical Defense) describe the feasibility of using miRNA microarray analysis to assess the effects of chemical warfare nerve agents on iCell Neurons.

Bradley, J et al. (Abstract 901, poster 203; Cyprotex and Axion Biosystems) demonstrate the use of multi-well MEAs to screen seizurogenic compounds on iCell Neurons to predict neural toxicity.

Wolfe, ML et al. (Abstract 1063, poster 508; MPI Research) discuss hepatotoxicity prediction using a high content imaging system to assess drug induced liver injury after treating human hepatocellular carcinoma Hep G2 cells, iCell Hepatocytes, and primary human hepatocytes with a variety of drug compounds.

Wilga, PC et al. (Abstract 1465, poster 522; CeeTox) describe a dual cell model (iCell Cardiomyocytes and HepaRG cells) that utilizes changes in cell health and function following exposure to a drug compound to differentiate heart toxicity from liver toxicity, demonstrating that the combined data predicted cardiac toxicity with greater conf
'/>"/>

SOURCE Cellular Dynamics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
2. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
3. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
4. EastBridge Investment Group Announces Merger with Cellular Biomedicine Group
5. CeeTox and Cellular Dynamics Collaborate to Offer Predictive In Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells
6. Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell Technologies
7. Cellular Dynamics Launches MyCell™ Services
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of AngioDynamics Inc. in Connection with Executive Compensation
9. Transonic Systems Selects Infinity Info Systems To Implement Microsoft Dynamics CRM To Drive Business Performance And Operational Excellence
10. Zimmer Announces 11% Increase in Quarterly Dividend for First Quarter of 2013
11. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 Persistence Market ... "Global Market Study on Ophthalmic Devices: Asia ... global ophthalmic devices market was valued at USD 29,171.5 million in ... of 6.5% from 2014 to 2020, to reach an ... Browse the full Global Market Study on Ophthalmic Devices:  ...
(Date:9/22/2014)... , Sept. 22, 2014  AVT, Inc. (OTC ... retailing systems and custom vending machines, announced today that ... Unit. This new, smaller sized unit is designed for ... practices. According to industry statistics, there are ... Opticwash is the world,s first automated kiosk ...
(Date:9/22/2014)... , Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) ... investigator at Emory University, presented long-term follow up data ... stem cells in the treatment of amyotrophic lateral sclerosis ... which occurred at the Annual Symposium on ALS of ... , on Friday, and was not open to the ...
Breaking Medicine Technology:Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4
... 29, 2011 CryoLife, Inc. (NYSE: CRY ... processing company, and Cardiogenesis Corporation (OTCQB: CGCP), a leading ... patients with refractory angina resulting from diffuse coronary artery ... both companies have approved a definitive agreement under which ...
... March 29, 2011 Tris Pharma, Inc., a specialty ... the MyKidz® Iron product line.  Since the ... loyal following of pediatricians, pediatric nurses and mothers.  When ... in a different direction, availability of MyKidz Iron™ became ...
Cached Medicine Technology:CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 2CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 3CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 4CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 5CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 6CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 7CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 8CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 9CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 10CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 11CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 12CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 13CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 14CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 15CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 16CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 17CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 18Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 2Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 3
(Date:9/22/2014)... York (PRWEB) September 22, 2014 ... the use of power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... a new report detailing the continued use of ... federal regulators that specifically discouraged these procedures. According ... that the potential cancer risks associated with power ...
(Date:9/22/2014)... Gray HealthDay Reporter MONDAY, ... woman wonders: What can I do to help ensure a ... as prescribed may play a role in reducing the risk ... The researchers found that mothers of children with autism were ... during pregnancy than those whose children seem to be developing ...
(Date:9/22/2014)... In a continued effort to support ... is launching an awareness campaign inspired by the ice ... aims to raise awareness and funds for the cause. ... in the air and trying to catch it while ... a nominee does not complete the challenge within 24 ...
(Date:9/22/2014)... Ind. Researchers have developed a chip capable ... use the new system to test the effectiveness ... new system, called a tumor-microenvironment-on-chip (T-MOC) device, will ... tumors and the barriers that prevent the targeted ... Purdue University associate professor of mechanical engineering., Researchers ...
(Date:9/22/2014)... 22, 2014 The New York Group ... Surgery at the Icahn School of Medicine at Mount ... Group for Plastic Surgery gives residents of New York ... team of world-renowned plastic surgeons performing innovative reconstructive and ... MD, who led NYGPS, was named the Director of ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:New chip promising for tumor-targeting research 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... 24 Sopherion Therapeutics, LLC, a biopharmaceutical company ... therapies, has announced the appointment of Dr. Marcel ... Affairs. Prior to joining Sopherion, Dr. Rozencweig was ... and a member of the Sopherion Protocol Development ...
... ON, Feb. 24 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: ... research and development of drug products delivered to and ... delivery technologies, today announced that Nuvo,s INSIGHT(TM) platform, developed ... fqubed, Inc., has been selected as one of four ...
... of Nearly 106 Million PrescriptionsStrong 2009 EPS Guidance ReaffirmedFourth-Quarter ... percent to $0.54 from $0.38 in 2007 , - ... from the 2003 spin-off, increased 37.2 percent to $0.59 ... volume of 26.7 million increased 9.4 percent from 2007 ...
... a medical imaging and diagnostic Company launches new Physician Billing Services ... billing services as part of its commitment to synergistically diversify the ... ... 2009 -- Bederra Corporation (Pink Sheets: BEDA), a medical ...
... 24 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... and year ended December 31, 2008.(Logo: http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO )For ... loss of $33.4 million, or $0.91 per share, compared ... per share, in the fourth quarter of 2007. Weighted ...
... Healthcare Workers from Hazardous Drug ExposureCOLUMBUS, Ohio, Feb. 24 ... the safe handling of hazardous drugs in the healthcare ... Safe Handling Awareness Month with Monday, April 20, 2009 ... The proclamation of National Safe Handling Awareness Month ...
Cached Medicine News:Health News:Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs 2Health News:Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist 2Health News:Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist 3Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 2Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 3Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 4Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 5Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 6Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 7Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 8Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 9Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 10Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 11Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 12Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 13Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 14Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 15Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 16Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 17Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 18Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 19Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 20Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 21Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 22Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 23Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 24Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 25Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 26Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 27Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 28Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 29Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 30Health News:Bederra Corporation Launches New Billing Services Division Expected to Add up to $500,000 in Revenue 2Health News:Bederra Corporation Launches New Billing Services Division Expected to Add up to $500,000 in Revenue 3Health News:Rigel Announces Fourth Quarter and Year End 2008 Financial Results 2
... The ACE Titanium Small Fragment System ... the surgeon with superior implants and user-friendly ... and cannulated screws, and fracture instrumentation is ... necessary armamentarium to utilize current and classic ...
... The CARDIA PDA Closure Device has ... the Patent Ductus Arteriosus. Introduced through standard ... safe and reliable method for the percutaneous ... size from 2mm-10mm within the ductus.,An integral ...
Swanson Finger Pins are stainless steel and available in one length and three diameters....
Round Bevel-Point Hook Pin available in 2.3mm, 3.1mm, 4.7mm, and 6.3mm sizes....
Medicine Products: